Geovax Labs, Inc. · NASDAQ:GOVX
Geovax Labs — Q2 2022 Earnings Presentation
17 slides from Geovax Labs's earnings presentation, Aug 4, 2022
Slide 1: Q2 Corporate Update: Conference call
More NV “> Se: di - Q2 Corporate Update:Conference call August 3, 2022 NASDAQ: GOVX
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements in this presentation may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstanc
Slide 3: GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update
GedVax> GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update Advancing Phase 2 Clinical Trials for COVID-19 and Immuno-Oncology Evaluation of Company’s Vaccine Platform Against Monkeypox Underway ATLANTA, GA, August 3, 2022 - GeoVax Labs, Inc. (NasdagCM: GOVX), a biotec
Slide 4: Clinical Developments Progressing
Phase 2 Clinical Developments Progressing
Slide 5: 2022 Focus
Cc GeoVax> Vaccines Serving Humanity a 2022 Focus. * Successfully advance the Phase 2 clinical programs in support of Gedeptin® and GEO-CMO4s1 + Ensure appropriate resources to support \ the IND-enabling initiatives of our priority Ne —_— [ internal programs and operational > enhancements and develo
Slide 6: Slide 6
Slide 7: Gedeptin
Gedeptin® Phase 2 : Advanced Head and Neck Cancers + FDA orphan drug status granted * Additional clinical sites to accelerate patient enrollment * Evaluating broader use of Gedeptin in conjunction with Immune Checkpoint Inhibitors (ICIs)
Slide 8: COVID-19 and Variants
COVID-19 and Variants GEO-CMOASI: Next-Gen Covid-19 vaccine; currently in two Phase 2 trials CMO2: Universal coronavirus vaccine candidate
Slide 9: GEO-CM04S1 Phase 2: For the Immunocompromised
Cc GedVax> es Serving Humanity GEO-CMO4SI1 Phase 2: For the Immunocompromised + As a primary vaccine in direct comparison to the Pfizer/BioNTech mRNA vaccine + Ist trial to specifically evaluate a Covid-19 vaccine in patients with hematologic malignancies
Slide 10: GEO-CM04S1 Phase 2: Booster
CGecvax> COVID Vaccine GEO-CMO4S1 Phase 2: Booster + Inthe healthy population following vaccination with an MRNA vaccine * Potential for broader and more durable protection versus a 3rd or 4th MRNA dose EEE,
Slide 11: Senate Appropriations Committee Releases FY23 SFOPs and Labor HHS Appropriations Bills
Senate Appropriations Committee Releases FY23 State and Foreign Operations (SFOPs) and Labor, Health and Human Services (Labor HHS) Appropriations Bills Jul 29,2022 The Senate Committee on Appropriations released its FY 2023 State, Foreign Operations, and Related Programs (SFOPs) (links to bill and
Slide 12: Monkeypox outbreak spreading: WHO declares global health emergency
Monkeypox outbreak spreading: WHO declares global health emergency +The World Health Organization announced the multi-country monkeypox outbreak is now a global public health emergency, following a July 23 meeting of the International Health Regulations Emergency Committee (EC). +This came just a mo
Slide 13: Financial Update
Financial Update 13
Slide 14: Consolidated Balance Sheet Information
14 GeoVax Labs, Inc. Consolidated Balance Sheet Information (amounts in thousands, except share information) Assets Cash and cash equivalents Other current assets Total current assets Property and other assets, net Total assets Liabilities and stockholders’ equity Total liabilities Stockholders’ equ
Slide 15: Consolidated Statements of Operations Information
GeoVax Labs, Inc. Consolidated Statements of Operations Information (amounts in thousands, except share and per share information) Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Grant and collaboration revenue $ = $ 80 $ 82 $ 190 Operating expenses Research and development
Slide 16: as ‘ a GGeVax>
——<— ’ . a as ‘ a GGeVax>
Slide 17: Vaccines Serving Humanity
Vaccines Serving Humanity